Cancer, Cardiotoxicity, Heart Failure
Conditions
Brief summary
Anthracycline (AC) chemotherapy has substantially reduced the mortality rate from several common cancers globally. Unfortunately, AC treatment is associated with up to 19% risk of heart failure (HF). Current standard of care for preventing AC induced HF (AIHF) is cardiac surveillance followed by initiation of treatment once HF is diagnosed. With this approach 89% of patients fail to recover heart function and 46% will experience adverse cardiac events. Therefore there is a need for effective preventive therapy to reduce the risk of AIHF. Based on small human studies, animal studies, and our own pilot data, statins are an ideal class of drug for this purpose. We will conduct a pilot double blinded, placebo controlled, randomized controlled trial to assess whether pre-treatment with statins before AC can prevent heart dysfunction. Eligible patients with cardiovascular risk factors scheduled to receive AC will be recruited. They will be randomized to statin therapy or placebo and followed until the end of cancer treatment. Primary outcome is the difference in cardiac MRI-determined left ventricular ejection fraction between pre-AC and end of treatment.
Detailed description
STUDY DESIGN: This is a double blind, placebo controlled randomized controlled trial (RCT). We will also use stratification to ensure that the proportion of patients with different malignancies is balanced between the study arms. PATIENT RECRUITMENT: Patients will be recruited from respective oncology clinics at Princess Margaret Hospital, Mount Sinai Hospital, St. Michael's Hospital, Sunnybrook Health Sciences Centre and Scarborough General Hospital. INTERVENTION: Patients will receive treatment with 40mg/day of atorvastatin or placebo started 2-10 days prior to the initiation of AC and continued for up to one month after completion of the AC portion of cancer treatment. CARDIAC MRI (CMR): Studies will be performed on a 3.0T scanner (Siemens) and will include complete function and tissue characterization. CMR studies will be performed pre-therapy, after completion of AC, and 2 years after completion of AC. After de-identification and randomization, a research assistant blinded to all clinical data will perform all CMR analysis using commercially available software. ECHOCARDIOGRAPHY: Routine echocardiography studies will be performed at baseline, post-anthracycline completion, and at 6 months, 1 year, and 2 years follow up. SERUM BIOMARKERS: Blood work will be obtained on the day of baseline imaging, immediately after each cycle of anthracycline, on the day of post treatment imaging, and at the 6 months, 1 year and 2 year follow up. At each time point, optional samples of bio-banking may be collected. Blood sample collection will be done locally at the participant's respective site and transferred to University Health Network (UHN) biobank for future analysis or analysis of markers that are not available at all sites (e.g. high sensitivity troponin I and BNP).
Interventions
DRUGAtorvastatin
Atorvastatin 40mg OD
DRUGPlacebo oral tablet
Placebo
Sponsors
Mount Sinai Hospital, Canada
Unity Health Toronto
Sunnybrook Health Sciences Centre
Scarborough General Hospital
University Health Network, Toronto
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients with one of the following malignancies requiring anthracycline based chemotherapy with a curative intent: breast cancer; aggressive lymphomas; leukemia (acute myelogenous leukemia, acute lymphoblastic leukemia, mixed phenotype acute leukemia) or; sarcoma 2. Patients with high cardiovascular risk defined as: I. ≥60 years and at least one of the following: i. Compromised cardiac function based on baseline LVEF \<55% measured by echocardiography or MUGA or moderate left sided valvular heart disease (moderate mitral or aortic regurgitation or stenosis) ii. Planned cumulative doxorubicin dose equivalent 200mg/m² or more iii. Prior anthracycline therapy at any cumulative dose or prior chest/mediastinal radiation therapy iv. Any one of hypertension, smoking, obesity (BMI≥30), history of cardiomyopathy or heart failure but with recovered LVEF to ≥ 50% OR II. Age \<60 years with one of the following: i. and at least 2 of the risk factors listed above (I i-iv) ii. type 2 diabetes with age \<40 iii. type 1 diabetes duration \<15 years OR III. High anthracycline dose defined as ≥250mg/m² of doxorubicin, ≥600mg/m² epirubicin, or other isoequivalent dose 3. Living within geographic area conducive to repeated clinical and imaging follow-up
Exclusion criteria
1. Participating in another clinical research study where randomization would be unacceptable 2. Previous history of statin intolerance 3. Already on statin therapy or known statin indicated condition: I. atherosclerosis i. myocardial infarction ii. acute coronary syndrome iii. stable angina iv. documented coronary disease by angiography (\>10% stenosis) v. stroke vi. TIA vii. documented carotid disease viii. peripheral arterial disease ix. claudication and/or ABI \<0.9 II. abdominal aortic aneurysm (\>3.0cm or previous aneurysm surgery) III. chronic kidney disease (\>3 months duration and ACR \>3.0mg/mmol or eGFR \<60mL/min/1.73m²) 4. CK level \>3x upper limit of normal 5. Evidence of hepatic dysfunction (ALT level \>2x upper limit of normal) 6. On a drug that is a strong inhibitor of cytochrome P450 3A4 or may require such treatment during the treatment period (because atorvastatin is metabolized by this pathway) 7. Significant valvular heart disease defined as severe stenotic or regurgitant lesions of any of the cardiac valves 8. Life expectancy less than 12 months 9. Contraindication to cardiac MRI (e.g. implanted pacemakers, ICDs, other implanted ferromagnetic objects unsafe for cardiac MRI or will result in significant artifact, eGFR \<30) 10. Creatinine \>177umol/L 11. Known history of uncontrolled hypothyroidism (TSH level \>1.5x upper limit of normal)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cardiac MRI measured LVEF within 4 weeks of anthracycline completion | Within 4 weeks of cancer therapy completion | Cardiac MRI LVEF at the end of treatment will be measured before cancer treatment and within 4 weeks after completion of anthracycline-based treatment. The pre-treatment measurement will facilitate a baseline adjusted comparison between placebo and statin treated groups. |
Other
| Measure | Time frame | Description |
|---|---|---|
| The incidence of cardiotoxicity | From start of anthracycline therapy to upto 4 weeks of anthracycline completion | defined by LVEF fall \>10% from pre-cancer treatment assessment to \<53% |
| Interruption of study drug due to side effects or permanent cessation of study drug or cancer treatment due to cardiac dysfunction | From start of anthracycline therapy to upto 4 weeks of anthracycline completion | as defined by reduction in drug dose or delay of cancer treatment by more than 1 week or permanent cessation |
| Troponin I | Maximal increase in Troponin I between pre-anthracycline therapy to within 4 weeks of anthracycline completion | Maximal increase in troponin I |
| Cardiac MRI measured LV end diastolic volume (LVEDV) and end systolic volume (LVESV) at the end of treatment | Within 4 weeks of anthracycline completion | these measures will be obtained at the same time as the LVEF measures with pre-treatment measurements facilitating a baseline adjusted comparison between placebo and statin treated groups |
| Myocardial strain | From start of anthracycline therapy to within 4 weeks of cancer therapy completion | Maximal change in myocardial strain |
| MRI tissue characterization parameters | Within 4 weeks of anthracycline completion | Maximal change in myocardial tissue characterization parameters as measured by cardiac MRI from pre-anthracycline treatment to within 4 weeks of anthracycline completion |
| BNP | From start of anthracycline therapy to within 4 weeks of cancer therapy completion | Maximal increase in BNP |
Countries
Canada
Outcome results
None listed